-
Mashup Score: 3Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma - 1 day(s) ago
Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma - 1 day(s) ago
The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The @EMA_News’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma. #mmsm #hematology #oncology https://t.co/zmTjo8bVrD
-
A real-world observational study of bispecific antibodies in relapsed/refractory multiple myeloma in the community oncology setting demonstrated the growing rate of their use in clinical practice, according to Ira Zackon, MD. #MMSM #hematology #oncology https://t.co/v9ZM2r6jUn https://t.co/bLJMIdOo3b